Trials / Withdrawn
WithdrawnNCT06518538
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
A Phase 2 Single Center Open-Label Trial to Evaluate Efficacy and Safety of Devimistat in Combination With Modified FOLFIRINOX (mFFX) in 2nd Line Patients With Metastatic Adenocarcinoma of the Pancreas
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Cornerstone Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Open label, randomized phase II study to evaluate efficacy and safety of CPI-613 + mFFX in patients with metastatic adenocarcinoma of the pancreas with age range of 18 to 75 years
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CPI-613, modified Folfirinox | * CPI-613, devimistat * mFFX: Oxaliplatin, Folinic acid, Fluorouracil and Irinotecan |
Timeline
- Start date
- 2024-08-15
- Primary completion
- 2026-08-01
- Completion
- 2026-11-01
- First posted
- 2024-07-24
- Last updated
- 2024-08-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06518538. Inclusion in this directory is not an endorsement.